Therapy of myelofibrosis (excluding JAK2 inhibitors)

International Journal of Hematology

Volumn 91, Issue 2, 2010, Pages 180-188

  Rambaldi, Alessandro ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Allogeneic transplantation; HDAC inhibitors; Myelofibrosis

Indexed keywords

AZACITIDINE; BORTEZOMIB; BUSULFAN; CLADRIBINE; CYCLOPHOSPHAMIDE; DANAZOL; EVEROLIMUS; FLUDARABINE; GIVINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; IMATINIB; LENALIDOMIDE; MELPHALAN; PANOBINOSTAT; POMALIDOMIDE; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; THYMOCYTE ANTIBODY; TIPIFARNIB; VORINOSTAT;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG MECHANISM; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOMODULATION; MOUTH ULCER; MUSCULOSKELETAL PAIN; MYELOFIBROSIS; NEUTROPENIA; PERIPHERAL NEUROPATHY; REVIEW; SEDATION; SIDE EFFECT; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOSIS; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; ENZYME INHIBITORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; PRIMARY MYELOFIBROSIS; STEROIDS;

EID: 77950917616     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0532-x     Document Type: Review

References (62)

1. JJ Lataillade O Pierre-Louis HC Hasselbalch, et al. 2008 Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence Blood 112 3026 3035 10.1182/blood-2008-06-158386 1:CAS:528:DC%2BD1cXht1OmtbfP 18669872
2. RL Levine DG Gilliland 2008 Myeloproliferative disorders Blood 112 2190 2198 10.1182/blood-2008-03-077966 1:CAS:528:DC%2BD1cXhtFCrurvM 18779404
3. G Barosi G Bergamaschi M Marchetti, et al. 2007 JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis Blood 110 4030 4036 10.1182/blood-2007-07-099184 1:CAS:528:DC%2BD2sXhtl2qsb%2FK 17712047 (Pubitemid 350248459)
4. G Barosi D Bordessoule J Briere, et al. 2005 Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET) Blood 106 2849 2853 10.1182/blood-2005-04-1520 1:CAS:528:DC%2BD2MXhtFantbbL 15994287 (Pubitemid 41510763)
5. A Tefferi G Barosi RA Mesa, et al. 2006 International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT) Blood 108 1497 1503 10.1182/blood-2006-03-009746 1:CAS:528:DC%2BD28Xpt1Slt7s%3D 16675707 (Pubitemid 44316114)
6. A Tefferi 2008 Primary myelofibrosis Cancer Treat Res 142 29 49 18283781
7. LN Faoro A Tefferi RA Mesa 2005 Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia Eur J Haematol 74 117 120 10.1111/j.1600-0609.2004.00370.x 1:CAS:528: DC%2BD2MXitVGnsL0%3D 15654901 (Pubitemid 40175314)
8. F Cervantes A Alvarez-Larran JC Hernandez-Boluda A Sureda M Torrebadell E Montserrat 2004 Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature Br J Haematol 127 399 403 10.1111/j.1365-2141.2004.05229.x 1:CAS:528: DC%2BD2cXhtVOms7jF 15521916 (Pubitemid 39536591)
9. Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer. 2008;112(12):2726-32. (Pubitemid 351969217)
10. P Guardiola JE Anderson G Bandini, et al. 1999 Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study Blood 93 2831 2838 1:CAS:528:DyaK1MXivVyltrc%3D 10216077 (Pubitemid 29200773)
11. DM Kerbauy TA Gooley GE Sale, et al. 2007 Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia Biol Blood Marrow Transplant 13 355 365 10.1016/j.bbmt.2006.11.004 17317589 (Pubitemid 46268262)
12. N Kroger E Holler G Kobbe, et al. 2009 Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Blood 114 5264 5270 10.1182/blood-2009-07-234880 10.1182/blood-2009-07-234880 19812383
13. SM Devine R Hoffman A Verma, et al. 2002 Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia Blood 99 2255 2258 10.1182/blood.V99.6.2255 1:CAS:528:DC%2BD38XitF2msb8%3D 11877308 (Pubitemid 34525517)
14. D Rondelli G Barosi A Bacigalupo, et al. 2005 Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia Blood 105 4115 4119 10.1182/blood-2004-11-4299 1:CAS:528:DC%2BD2MXktlSrt7g%3D 15671439 (Pubitemid 40656163)
15. F Patriarca A Bacigalupo A Sperotto, et al. 2008 Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) Haematologica 93 1514 1522 10.3324/haematol.12828 10.3324/haematol.12828 1:CAS:528:DC%2BD1cXhtl2gurzE 18728030
16. N Kroger J Thiele A Zander, et al. 2007 Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis Exp Hematol 35 1719 1722 10.1016/j.exphem.2007.08.022 17976523 (Pubitemid 47633778)
17. Bacigalupo A, Soraru M, Dominietto A, et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: A predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant. 2009. doi: 10.1038/bmt.2009.188.
18. SO Ciurea B Sadegi A Wilbur, et al. 2008 Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation Br J Haematol 141 80 83 10.1111/j.1365-2141.2008.07010.x 18324970 (Pubitemid 351350607)
19. N Kroger RA Mesa 2008 Choosing between stem cell therapy and drugs in myelofibrosis Leukemia 22 474 486 10.1038/sj.leu.2405080 1:STN:280: DC%2BD1c7nsVOktA%3D%3D 18185525 (Pubitemid 351386717)
20. N Kroger A Badbaran E Holler, et al. 2007 Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis Blood 109 1316 1321 10.1182/blood-2006-08-039909 17018857 (Pubitemid 46220685)
21. SG Papageorgiou A Castleton A Bloor PD Kottaridis 2006 Allogeneic stem cell transplantation as treatment for myelofibrosis Bone Marrow Transplant 38 721 727 10.1038/sj.bmt.1705516 1:STN:280:DC%2BD28jkvVersA%3D%3D 17013423 (Pubitemid 44756441)
22. JE Anderson A Tefferi F Craig, et al. 2001 Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis Blood 98 586 593 10.1182/blood.V98.3.586 10.1182/blood.V98.3.586 1:CAS:528:DC%2BD3MXlsFKrtLg%3D 11468154
23. A Tefferi RA Mesa LA Gray, et al. 2002 Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia Blood 99 3854 3856 10.1182/blood-2001-12-0154 1:CAS:528:DC%2BD38XjvVGnu70%3D 11986248 (Pubitemid 34534563)
24. RA Mesa JK Camoriano SM Geyer, et al. 2007 A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia Leukemia 21 1964 1970 10.1038/sj.leu.2404816 1:CAS:528:DC%2BD2sXptlSrs7Y%3D 17581608 (Pubitemid 47299971)
25. O Wagner-Ballon DF Pisani T Gastinne, et al. 2007 Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice Blood 110 345 353 10.1182/blood-2006-10-054502 1:CAS:528:DC%2BD2sXnsVaitrg%3D 17374740 (Pubitemid 47026853)
26. Mesa RA, Verstovsek S, Rivera C, et al. Bortezomib therapy in myelofibrosis: a phase II clinical trial. Leukemia. 2008;22:1636-8.
27. RA Mesa DP Steensma A Pardanani, et al. 2003 A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia Blood 101 2534 2541 10.1182/blood-2002-09- 2928 1:CAS:528:DC%2BD3sXivVWgur4%3D 12517815 (Pubitemid 36857609)
28. A Tefferi J Cortes S Verstovsek, et al. 2006 Lenalidomide therapy in myelofibrosis with myeloid metaplasia Blood 108 1158 1164 10.1182/blood-2006-02- 004572 10.1182/blood-2006-02-004572 1:CAS:528:DC%2BD28Xot1ymtL0%3D 16609064 (Pubitemid 44232010)
29. A Tefferi S Verstovsek G Barosi, et al. 2009 Pomalidomide is active in the treatment of anemia associated with myelofibrosis J Clin Oncol 27 4563 4569 10.1200/JCO.2008.21.7356 10.1200/JCO.2008.21.7356 1:CAS:528:DC%2BD1MXhtlCns77E 19652059
30. Passamonti F, Gattoni E, Cervantes F, et al. Pomalidomide therapy in myelofibrosis: 2-year follow-up of a randomized phase 2 study. ASH Annual Meeting Abstracts. 2009;114:1904.
31. Opalinska J, Sohal D, Thompson R, et al. Global DNA methylation profiling demonstrates that idiopathic myelofibrosis is characterized by a distinct epigenetic signature with aberrant methylation changes in genes involved in inflammation and hematopoiesis. ASH Annual Meeting Abstracts. 2007;110:1536.
32. L Pieri P Guglielmelli C Bogani A Bosi AM Vannucchi 2008 Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele Leuk Res 32 516 517 10.1016/j.leukres.2007.07.001 1:CAS:528:DC%2BD1cXislWjtrw%3D 17706283 (Pubitemid 351295914)
33. J Shi Y Zhao T Ishii, et al. 2007 Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis Cancer Res 67 6417 6424 10.1158/0008-5472.CAN-07-0572 1:CAS:528:DC%2BD2sXnsVyqtbw%3D 17616702 (Pubitemid 47037526)
34. M Fernandez-Mercado V Cebrian B Euba, et al. 2008 Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms Leuk Res 32 1638 1640 10.1016/j.leukres.2008.03.014 1:CAS:528:DC%2BD1cXntlGgsLc%3D 18440067
35. L Teofili M Martini T Cenci, et al. 2008 Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases Int J Cancer 123 1586 1592 10.1002/ijc.23694 1:CAS:528:DC%2BD1cXhtV2ru7%2FI 18623127
36. Quintas-Cardama A, Tong W, Kantarjian H, et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/ polycythemia vera myelofibrosis. Leukemia. 2008;22:965-70.
37. PA Marks R Breslow 2007 Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Nat Biotechnol 25 84 90 10.1038/nbt1272 1:CAS:528:DC%2BD2sXis1GrsQ%3D%3D 17211407 (Pubitemid 46087907)
38. MT Voso V Santini C Finelli, et al. 2009 Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes Clin Cancer Res 15 5002 5007 10.1158/1078-0432.CCR-09-0494 1:CAS:528:DC%2BD1MXptl2gtrg%3D 19638460
39. Y Inoue T Suzuki M Takimoto, et al. 2005 Treatment with valproic acid for myelofibrosis with myeloid metaplasia Ann Hematol 84 833 834 10.1007/s00277-005-1104-7 16132902 (Pubitemid 43008560)
40. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769-84. (Pubitemid 44348499)
41. OA O'Connor ML Heaney L Schwartz, et al. 2006 Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies J Clin Oncol 24 166 173 10.1200/JCO.2005.01.9679 16330674 (Pubitemid 46630509)
42. P Richardson C Mitsiades K Colson, et al. 2008 Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma Leuk Lymphoma 49 502 507 10.1080/10428190701817258 1:CAS:528:DC%2BD1cXit1Cmsbc%3D 18297527 (Pubitemid 351298334)
43. M Duvic R Talpur X Ni, et al. 2007 Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 109 31 39 10.1182/blood-2006-06-025999 1:CAS:528: DC%2BD2sXivVyrt7g%3D 16960145 (Pubitemid 46053039)
44. Lee J. Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis. Ann Hematol. 2008;88:699-700.
45. J Golay L Cuppini F Leoni, et al. 2007 The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells Leukemia 21 1892 1900 10.1038/sj.leu.2404860 1:CAS:528:DC%2BD2sXptlSrsbo%3D 17637810 (Pubitemid 47299961)
46. M Galli S Salmoiraghi J Golay, et al. 2010 A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma Ann Hematol 89 185 190 10.1007/s00277-009-0793-8 1:CAS:528:DC%2BC3cXjt1yltw%3D%3D 19633847
47. V Guerini V Barbui O Spinelli, et al. 2008 The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F) Leukemia 22 740 747 10.1038/sj.leu.2405049 1:CAS:528:DC%2BD1cXks12rt7g%3D 18079739 (Pubitemid 351552623)
48. Rambaldi A, Dellacasa CM, Salmoiraghi S, et al. A phase 2a study of the histone-deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms. ASH Annual Meeting Abstracts. 2008;112:100.
49. Mascarenhas J, Wang X, Rodriguez A, et al. A phase I study of LBH589, a novel histone deacetylase inhibitor in patients with primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (Post-PV/ET MF). ASH Annual Meeting Abstracts. 2009;114:308.
50. Vannucchi AM, Bogani C, Bartalucci N, et al. The mTOR inhibitor, RAD001, inhibits the growth of cells from patients with myeloproliferative neoplasms. ASH Annual Meeting Abstracts. 2009;114:2914.
51. Vannucchi AM, Guglielmelli P, Gattoni E, et al. RAD001, an inhibitor of mTOR, shows clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (PPV/PET MF). ASH Annual Meeting Abstracts. 2009;114:307.
52. E Lofvenberg A Wahlin 1988 Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea Eur J Haematol 41 375 381 1:STN:280:DyaL1M%2FmsFSnug%3D%3D 3197824 (Pubitemid 19003754)
53. MC Petti R Latagliata T Spadea, et al. 2002 Melphalan treatment in patients with myelofibrosis with myeloid metaplasia Br J Haematol 116 576 581 10.1046/j.0007-1048.2001.03331.x 1:CAS:528:DC%2BD38XislSns7s%3D 11849213 (Pubitemid 34178656)
54. JC Chang HM Gross 1988 Remission of chronic idiopathic myelofibrosis to busulfan treatment Am J Med Sci 295 472 476 10.1097/00000441-198805000-00011 1:STN:280:DyaL1c3jvVKnsg%3D%3D 3376991
55. F Cervantes A Alvarez-Larran A Domingo E Arellano-Rodrigo E Montserrat 2005 Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients Br J Haematol 129 771 775 10.1111/j.1365-2141.2005.05524.x 1:CAS:528: DC%2BD2MXms1ehsL8%3D 15953003 (Pubitemid 40904527)
56. D Przepiorka S Giralt I Khouri R Champlin C Bueso-Ramos 1998 Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases Am J Hematol 57 24 28 10.1002/(SICI)1096-8652(199801)57:1<24::AID-AJH4>3.0.CO;2-3 1:STN:280:DyaK1c%2FosVChug%3D%3D 9423812 (Pubitemid 28047194)
57. A Daly K Song T Nevill, et al. 2003 Stem cell transplantation for myelofibrosis: a report from two Canadian centers Bone Marrow Transplant 32 35 40 10.1038/sj.bmt.1704075 1:STN:280:DC%2BD3s3oslarug%3D%3D 12815476 (Pubitemid 36850278)
58. HJ Deeg TA Gooley ME Flowers, et al. 2003 Allogeneic hematopoietic stem cell transplantation for myelofibrosis Blood 102 3912 3918 10.1182/blood-2003- 06-1856 1:CAS:528:DC%2BD3sXpsFamurY%3D 12920019 (Pubitemid 37486970)
59. P Mittal RM Saliba SA Giralt, et al. 2004 Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia Bone Marrow Transplant 33 1005 1009 10.1038/sj.bmt.1704472 1:STN:280:DC%2BD2c3ivFKntQ%3D%3D 15048141 (Pubitemid 38744786)
60. M Ditschkowski DW Beelen R Trenschel M Koldehoff AH Elmaagacli 2004 Outcome of allogeneic stem cell transplantation in patients with myelofibrosis Bone Marrow Transplant 34 807 813 10.1038/sj.bmt.1704657 1:STN:280: DC%2BD2crhsFWlsg%3D%3D 15354205 (Pubitemid 39467893)
61. M Merup V Lazarevic H Nahi, et al. 2006 Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens Br J Haematol 135 367 373 10.1111/j.1365-2141.2006.06302.x 1:CAS:528:DC%2BD28Xht1GrurvE 16972981 (Pubitemid 44484845)
62. DS Snyder J Palmer AS Stein, et al. 2006 Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis Biol Blood Marrow Transplant 12 1161 1168 10.1016/j.bbmt.2006.06. 014 17085309 (Pubitemid 44660860)